drugset / Trial / NCT00979316

Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects

NCT00979316

Phase 1 Completed 62 enrolled Bristol-Myers Squibb
RandomizedCrossoverQuadruple-blind

Summary

The purpose of this study is to determine the effect of BMS-708163 on the QTc interval (QT interval corrected for heart rate).

Timeline

Start
2009-09
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Avagacestat Small molecule 200 mg Oral
Subject Avagacestat Small molecule 800 mg Oral
Comparator Moxifloxacin Small molecule 400 mg Oral

Indications